| 25.91 Delayed Data As of Sep 13 |  -0.19 / -0.73%Today’s Change | 24.06 Today|||52-Week Range 32.94 | -- Year-to-Date |
| Alexion (ALXN) In-licenses Amyloidosis Candidate In Japan Sep 10 / Zacks.com - Paid Partner Content |
| Previous close | 26.10 |
| Today’s open | 26.09 |
| Day’s range | 25.33 - 26.53 |
| Volume | 194,077 |
| Average volume (3 months) | 324,369 |
| Market cap | $3.0B |
| Earnings growth (last year) | -278.84% |
| Earnings growth (this year) | -- |
| Earnings growth (next 5 years) | -- |
| Revenue growth (last year) | -- |
| P/E ratio | NM |
| Price/Sales | -- |
| Price/Book | -- |
| Today’s change | Today’s % change | |
|---|---|---|
| AKRXAkorn Inc | -0.10 | -2.67% |
| TEVATeva Pharmaceutical | -0.24 | -2.93% |
| BGNEBeiGene Ltd | +1.10 | +0.83% |
| Next reporting date | November 27, 2019 |
| EPS forecast (this quarter) | -$0.96 |
| Annual revenue (last year) | $0.00 |
| Annual profit (last year) | -$130.7M |
| Net profit margin | -- |
Sector Health Technology |
Industry Pharmaceuticals: Generic |
SVP- Asset Acquisition, Strategy & Operations Michael Henderson |
Chief Financial Officer Brian C. Stephenson |
Corporate headquarters Palo Alto, California |
